HCW Biologics Inc. received confirmation on June 4, 2025, that it is in compliance with Nasdaq listing rules following a successful financial restructuring, including $6.6 million in note conversions and a $5 million equity financing; the company expects continued listing on the Nasdaq Capital Market.